Published 23 hours ago • loading... • Updated 22 hours ago

Study Shows Nerandomilast Slowed Lung Function Decline in Progressive Pulmonary Fibrosis

Summary by Managed Healthcare Executive

Results come after positive results from a trial among people with idiopathic pulmomary disease.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

Managed Healthcare Executive

Study Shows Nerandomilast Slowed Lung Function Decline in Progressive Pulmonary Fibrosis

Results come after positive results from a trial among people with idiopathic pulmomary disease.

22 hours ago

Read Full Article

El Independiente

Two Global Clinical Trials with 142 Spanish Patients in 26 Hospitals Contribute to Bringing Together New Solutions for Pulmonary Fibrosis

Boehringer Ingelheim has presented, within the framework of the Separ 2025 Congress, the results of its latest clinical trials Fibroneer-IPF and Fibroneer-ILD, two phase III international studies in which 26 hospitals and 142 patients have participated throughout the national territory, contributing to research into pulmonary fibrosis, a condition that affects up to 9.2 million people worldwide and generates a great impact on patients. Pulmonary…

23 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right